At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
F901318 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
In Brief
A Phase 1 clinical trial evaluating F901318 and Placebo for Invasive Aspergillosis. Completed, enrolled 40 participants across 1 site.
Detailed Summary
F901318 is a potent new antifungal agent for the treatment of systemic fungal infections. This study will test it for the first time in man with the objective of assessing its safety, tolerability and pharmacokinetic profile.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInvasive Aspergillosis
CountriesUnited Kingdom
CollaboratorsSimbec Research
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartAug 2014
Primary CompletionOct 2014
TodayJul 2026
First PostedMay 20, 2014
Enrollment StartAug 1, 2014
Primary CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.1 years ago
Interventions
F901318drug
Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities. Pharmacokinetic profile
Placebodrug
Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities